Raptor Pharmaceuticals Corp is a US-based biotechnology company focused on discovering and developing drug candidates and drug-targeting platforms for various brain disorders, genetic disorders, neurodegenerative diseases, and cancer. Their clinical-stage products, such as DR Cysteamine and Convivia, are being tested for the treatment of nephropathic cystinosis, non-alcoholic steatohepatitis, and ALDH2 deficiency. They also have preclinical development products like HepTide, WntTide, and NeuroTrans for the treatment of hepatocellular carcinoma, breast cancer, and neurodegenerative diseases. Raptor has collaboration agreements with the University of California, San Diego for clinical studies and was founded in 2005.